Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.

<h4>Objective</h4>The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (net...

Full description

Bibliographic Details
Main Authors:	Ekaterina A Bryushkova, Valeria D Skatova, Zinaida Y Mutovina, Alena I Zagrebneva, Daria S Fomina, Tatyana S Kruglova, Anna A Akopyan, Irina D Strazhesko, Sergey A Lukyanov, Olga N Tkacheva, Maryana A Lysenko, Dmitry M Chudakov
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0273340

Similar Items

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01)

Real-world experience with netakimab in the treatment of spondyloarthritis
by: Alexey D. Meshkov, et al.
Published: (2023-12-01)

Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit
by: Ulyana A. Markina, et al.
Published: (2022-06-01)

Netakimab in the therapy of psoriatic onychodystrophy
by: O. V. Zhukova, et al.
Published: (2022-08-01)

Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment
by: Alexey I. Khripun, et al.
Published: (2022-06-01)

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19
by: Tatyana S. Kruglova, et al.
Published: (2021-11-01)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
by: Yuichi Kojima, et al.
Published: (2022-04-01)

Successful use of Netakimab in the treatment of psoriasis accompanied by the psoriatic onychodystrophy
by: N. N. Potekaev, et al.
Published: (2020-10-01)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
by: John Roddy, MD, et al.
Published: (2022-05-01)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
by: Mar Masiá, et al.
Published: (2021-11-01)

Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice
by: Andrey L. Bakulev, et al.
Published: (2023-12-01)

Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis
by: Jin Zhang, et al.
Published: (2023-11-01)

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
by: T. V. Korotaeva, et al.
Published: (2020-11-01)

Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids
by: Ekaterina A. Nikitina, et al.
Published: (2023-07-01)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
by: Jerin Jose Cherian, et al.
Published: (2022-10-01)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
by: Carlos K. H. Wong, et al.
Published: (2022-05-01)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
by: Farzaneh Dastan, et al.
Published: (2023-10-01)

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy
by: Anna Lebedeva, et al.
Published: (2022-07-01)

Cardiorenal syndrome in patients with rheumatoid arthritis
by: Z. Yu. Mutovina, et al.
Published: (2019-09-01)

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study
by: Marina S. Lebedkina, et al.
Published: (2023-08-01)

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01)

Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
by: Botond Lakatos, et al.
Published: (2022-12-01)

Baricitinib for alopecia areata
by: Hamza Imran, et al.
Published: (2023-04-01)

Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022-03-01)

The informative value of CD3+CD4+ and CD3+CD8+ T-cell count and cHIS scale as predictors of severe COVID-19 when using interleukin-6 receptor blockers in the in-hospital setting
by: Tatiana S. Kruglova, et al.
Published: (2022-12-01)

Efficacy of baricitinib in severe coronavirus disease 2019
by: Ahmed M A E F Amer, et al.
Published: (2023-01-01)

Resolution of the Research Council of Experts on the place of netakimab, a new interleukin-17a inhibitor, in the therapy of ankylosing spondylitis
by: article Editorial
Published: (2020-06-01)

Resolution of the Scientific Council of Experts: “The place of netakimab, a new inhibitor of IL-17A, in the treatment of psoriatic arthritis
by: article Editorial
Published: (2020-09-01)

Baricitinib for the treatment of atopic dermatitis
by: Amelia Melo, et al.
Published: (2022-07-01)

Corynebacterium amycolatum infective endocarditis in a patient with severe COVID-19: a case report
by: Andreev S.S., et al.
Published: (2022-09-01)

Gut Microbiome in Post-COVID-19 Patients Is Linked to Immune and Cardiovascular Health Status but Not COVID-19 Severity
by: Olga N. Tkacheva, et al.
Published: (2023-04-01)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-11-01)

Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
by: A. L. Bakulev, et al.
Published: (2019-10-01)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
by: Daria S. Fomina, et al.
Published: (2023-10-01)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
by: A. E. Karateev
Published: (2020-09-01)

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019-07-01)

Pinpointing the tumor-specific T cells via TCR clusters
by: Mikhail M Goncharov, et al.
Published: (2022-04-01)

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
by: Fautrel, B, et al.
Published: (2018)